NEW YORK (GenomeWeb News) – Exiqon today reported that its third quarter revenues declined around 1 percent year over year.

The Danish firm reported total revenues of DKK 29.8 million ($5.5 million) for the quarter, compared to DKK 30.1 million for Q3 2012. It said that its research product sales and services, excluding OEM, increased 17 percent year over year to DKK 26.5 million, with North American sales for those products up 44 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.